Picton Mahoney Asset Management Decreases Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Picton Mahoney Asset Management lowered its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,938 shares of the medical research company’s stock after selling 1,633 shares during the period. Picton Mahoney Asset Management’s holdings in IQVIA were worth $6,925,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Everpar Advisors LLC purchased a new stake in IQVIA during the 4th quarter worth about $231,000. Charles Schwab Investment Management Inc. raised its position in shares of IQVIA by 2.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,160,716 shares of the medical research company’s stock valued at $268,566,000 after buying an additional 28,598 shares during the last quarter. Private Advisor Group LLC lifted its stake in shares of IQVIA by 8.2% during the fourth quarter. Private Advisor Group LLC now owns 5,215 shares of the medical research company’s stock valued at $1,207,000 after buying an additional 397 shares during the period. Spire Wealth Management boosted its position in IQVIA by 9.1% during the fourth quarter. Spire Wealth Management now owns 1,016 shares of the medical research company’s stock worth $219,000 after acquiring an additional 85 shares during the last quarter. Finally, Metis Global Partners LLC grew its stake in IQVIA by 4.2% in the 4th quarter. Metis Global Partners LLC now owns 8,258 shares of the medical research company’s stock worth $1,911,000 after acquiring an additional 331 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 0.5 %

Shares of IQV stock traded down $1.26 during trading hours on Wednesday, reaching $227.88. The company had a trading volume of 577,500 shares, compared to its average volume of 964,922. The company has a market capitalization of $41.52 billion, a P/E ratio of 31.13, a price-to-earnings-growth ratio of 2.16 and a beta of 1.52. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The stock’s fifty day simple moving average is $243.28 and its 200 day simple moving average is $225.03. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.88 and a current ratio of 0.88.

IQVIA (NYSE:IQV) last posted its earnings results on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. The business had revenue of $3.87 billion for the quarter, compared to analysts’ expectations of $3.80 billion. During the same period in the previous year, the company posted $2.54 earnings per share. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IQV has been the topic of several analyst reports. Guggenheim cut IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Truist Financial lowered their price target on IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a report on Friday, May 3rd. SVB Leerink assumed coverage on shares of IQVIA in a report on Monday, February 26th. They issued an “outperform” rating and a $290.00 target price for the company. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Friday, February 16th. Finally, Evercore ISI lowered their price objective on shares of IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a research note on Friday, May 3rd. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $257.57.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the completion of the sale, the insider now owns 20,836 shares in the company, valued at approximately $5,031,894. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, insider Kevin C. Knightly sold 8,607 shares of IQVIA stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the completion of the transaction, the insider now directly owns 5,251 shares in the company, valued at $1,313,642.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now owns 20,836 shares in the company, valued at approximately $5,031,894. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,285 shares of company stock valued at $10,331,003. 1.60% of the stock is currently owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.